Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 13, 1998

View Archived Issues

Matrix Pharmaceutical: Q3 1998 highlights

Unimed: Q3 1998 highlights

Flamel Technologies: Q3 1998 highlights

BioCryst: Q3 1998 highlights

Leflunomide reduces symptoms of rheumatoid arthritis, slows disease progression in new studies

New data show rhuMAb-E25 may reduce seasonal allergy symptoms

SB-205553 used to investigate role of 5-HT2C receptor antagonists in PD therapy

Ligand and Elan finalize strategic alliance

Bristol-Myers Squibb initiates phase III HBV clinical trials; phase II data reported

OSI Pharmaceuticals updates anticancer programs

McMaster University researchers target potential gene therapies for arthritis

Sepracor announces results of phase II pilot trial for (S)-oxybutynin

Data and safety monitoring board recommends continuation of Bextra study

BG-9719 has potent natriuretic effects in patients with CHF

Xenova to begin phase II efficacy trials of XR-5000

OraVax to merge with Peptide Therapeutics

New compounds from Glaxo Wellcome and their use as beta3-adrenoceptor agonists

Hydroxamic acid compounds as inhibitors of TNF production and/or MMPs

SCRAS presents new series of NOS and lipid peroxidation inhibitors

Taiho isolates new antiproliferative agent from Nocardiopsis strain

Antibacterial compounds from Merck act by inhibiting Mur D

VPA-985 characterized as potent, selective, orally active V2 antagonist

Serum complement activation is implicated in the pathogenesis of CHF

Vasopressin V2 receptor antagonist beneficial in mouse model of PKD

OPC-21268 improves glomerulonephritis in hypercholesterolemic rats, nephropathy in diabetic rats

Neurobiological Technologies initiates phase IIb trial of memantine

Renal protective effect of efonidipine in hypertensive patients

New cytokine modulator from Schering-Plough is active in models of endotoxemia

Mizoribine evaluated in children with frequently relapsing nephrotic syndrome

SB team attempts to identify the source of antiparkinsonian activity of SKF-83959

Final results presented from phase II Vitrase trial

Leo's oral vitamin D analogue induces regression, inhibits tumor growth in hepatocellular carcinoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...